• $39.9M
    Market Cap
  • -1.06%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 17
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

AGIG: Abbott Cooper PLLC Announces Investigation on Behalf of Abundia Global Impact Group, Inc. (Formerly Houston American Energy Corp.) Stockholders

Abbott Cooper PLLC has announced investigations into potential fiduciary duty violations and wrongdoing by the boards of directors of three companies: Abundia Global Impact Group, Inc. (formerly Houston American Energy Corp.), Estrella Immunopharma, Inc., and Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The law firm is seeking stockholders who held shares continuously since July 1, 2025, or earlier to join the investigations on a contingency fee basis.

07/08/2026, 11:06 PM • GlobeNewswire

ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders

Abbott Cooper PLLC is investigating potential fiduciary duty violations and wrongdoing by Estrella Immunopharma's board of directors. The law firm is seeking stockholders to join the investigation on a contingency fee basis.

07/08/2026, 10:54 PM • GlobeNewswire

Peers

  • IMMX
    IMMIX BIOPHARMA
    $10.84+3.04%
    Market Cap$790.9M
    1-Year Change+264.01%
  • GLSI
    GRNWICH LIFESCI
    $18.58+0.05%
    Market Cap$290.6M
    1-Year Change+71.79%
  • SRZN
    SURROZEN
    $22.810.00%
    Market Cap$269.2M
    1-Year Change+164.92%
  • TLSA
    TIZIANA LIFE SCI
    $1.34+0.41%
    Market Cap$143.7M
    1-Year Change-10.14%
  • ONCY
    ONCOLYTICS
    $0.90-3.11%
    Market Cap$105.9M
    1-Year Change-22.59%
  • EXOZ
    Exozymes
    $6.38+0.16%
    Market Cap$64.7M
    1-Year Change-35.08%
  • TIL
    INSTIL BIO
    $7.640.00%
    Market Cap$52.2M
    1-Year Change-68.80%
  • ATOS
    ATOSSA THERPTCS
    $2.36-1.67%
    Market Cap$23.6M
    1-Year Change-82.92%
  • TVGN
    TEVOGEN BIO
    $5.000.00%
    Market Cap$21.3M
    1-Year Change-92.06%
  • ANEB
    Anebulo Pharma
    $0.47+40.41%
    Market CapN/A
    1-Year Change-79.11%

Statistics

More
Day Range
$0.86
$0.97
$0.88
1-Year Range
$0.82
$3.05
$0.88
Latest Close$0.88
Change
-$0.05 (-5.86%)
Volume21,983
Market Cap$39.9M
Shares Outstanding43.0M
P/E (TTM)-2.68
Diluted EPS (TTM)-$0.35
Enterprise Value$38.0M

Information as of 07/13/2026

Company Profile

ESTRELLA IMMUNOPHARMA INC
https://www.estrellabio.com
$39.9M
Market Cap
-$13.3M
Net Income
Sector: Healthcare
Industry: Biotechnology
5858 Horton Street, EmeryVille, CA, United States, 94608
510 318 9098

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Key Executives

  • Cheng Liu
  • Jiandong Xu

Current Ownership Distribution

  • Insiders26.3M (61.10%)
  • Other9.1M (21.14%)
  • Institutions5.2M (12.03%)
  • Mutual Funds2.5M (5.73%)